Most Read Articles
Pearl Toh, 08 Jan 2021
Combining the anti-PD-1 antibody sintilimab and a bevacizumab biosimilar significantly improves survival compared with the standard treatment of sorafenib in the first-line setting for patients with advanced, unresectable hepatocellular carcinoma (HCC), according to the ORIENT-32 study presented at ESMO Asia 2020.
Dr Margaret Shi, 15 Jan 2021

Cancer patients at are an increased risk of severe coronavirus disease 2019 (COVID-19) and should be positioned at high priority for vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) regardless of age, according to statements issued by the European Society for Medical Oncology (ESMO).

Excerpts from the MY-COMPASSION Expert Meeting

30 Jan 2019
BTcP is defined as: “A transient exacerbation of pain that occurs either spontaneously, or in relation to a specific predictable or unpredictable trigger, despite relatively stable and adequately controlled background pain”.1,2 While there are various pain profiles associated with BTcP, a BTcP episode is typically severe, reaching peak pain intensity within 1–3 minutes from onset and is short in duration (ie, subsiding within 30 minutes).In Malaysia, opioids such as oral immediate-release(IR), intravenous (IV) and subcutaneous (SC) morphine are prescribed as ‘rescue’ medications for BTcP.2 IR opioids reach peak concentrations around 1 hour post-administration,and have a half-life of 3–6 hours, which may be suitable for longer duration BTcP episodes, but may not sufficiently address ‘sharp’, short-duration BTcP.2 In contrast, the faster onset of action seen in ROOs (eg, SLF which reaches peak plasma concentrations within 30–60 minutes post-administration) may be better suited for such episodes of BTcP.3,4

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 08 Jan 2021
Combining the anti-PD-1 antibody sintilimab and a bevacizumab biosimilar significantly improves survival compared with the standard treatment of sorafenib in the first-line setting for patients with advanced, unresectable hepatocellular carcinoma (HCC), according to the ORIENT-32 study presented at ESMO Asia 2020.
Dr Margaret Shi, 15 Jan 2021

Cancer patients at are an increased risk of severe coronavirus disease 2019 (COVID-19) and should be positioned at high priority for vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) regardless of age, according to statements issued by the European Society for Medical Oncology (ESMO).